|
Our vision is to improve the lives of those
affected by respiratory diseases and those who
provide care to them.
- - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - -
In 2006, we celebrated 100 years of innovation
in the field of aerosol science and inhalation
technology.
PARI is made up of a worldwide network of
companies, each with a specific focus in
developing or improving aerosol therapies. We
dominate the field of nebulized liquid drug aerosol
delivery.
PARI products are considered the “Gold Standard”
for new nebulized medications in development
and used in clinical trials. Pharmaceutical
companies with approved medications that used PARI
products in clinical trials include:
AccuNeb® (Dey) for asthma
Brovana® (Sepracor) for COPD
DuoNeb® (Dey) for COPD, asthma
Perforomist (Dey) for COPD
Pulmicort Respules® (AstraZeneca) for asthma
Pulmozyme® (Genentech) for cystic fibrosis
TOBI® (Novartis) for cystic fibrosis
Xopenex® (Sepracor) for asthma
Currently, PARI products are being used in over 20
additional clinical trials in the development of
new nebulized treatments.
|
